HC Wainwright & Co. Maintains Buy on C4 Therapeutics, Lowers Price Target to $17
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on C4 Therapeutics (NASDAQ:CCCC) but lowers the price target from $25 to $17.
August 09, 2023 | 10:44 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
C4 Therapeutics' price target has been lowered from $25 to $17 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for C4 Therapeutics by HC Wainwright & Co. indicates a potential decrease in the stock's value in the short term. However, the maintenance of the 'Buy' rating suggests that the analyst still sees potential in the company's long-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100